Skip to main content

Agilent's Bio-Analytical Fiscal Q1Revenues Rise 22 Percent as Life Sciences Grows 23 Percent

NEW YORK (GenomeWeb News) — Agilent Technologies said late yesterday that fiscal first-quarter revenues increased 10 percent as R&D spending increased 1.8 percent and profit declined after a divestiture during the same period last year caused the company to report a large gain.
Total receipts for the three months ended Jan. 31 increased to $1.25 billion from $1.17 billion year over year.
Revenue for the company’s Bio-Analytical Measurement segment increased 22 percent to $455 million from $373 million year over year.   
Life Sciences revenue was up 23 percent to $195 million. The company said that growth was “driven by year-end spending in pharmaceutical and biotech,” and sales of the company’s liquid chromatographers.
R&D spending increased to $168 million from $165 million year over year.
The company said net income decreased to $150 million from $2.09 billion in the year-ago period, which included $1.8 billion in income from the sale of the company’s semiconductor products and services business.
Agilent said it had around $2.1 billion in cash and equivalents as of Jan. 31.
For the second quarter of 2007, the company said it expects revenues between $1.3 billion and 1.4 billion.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.